Insmed Incorporated - Common Stock (INSM)

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for

Stanley Druckenmiller is considered one of the greatest investors of all time.

This online ticket marketplace debuted in September, but has struggled thus far.

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

This Investor Sold $1.9 Million in AMSC Stock Ahead of 35% Post-Earnings Crash

Essex Investment Buys $7.1 Million Globalstar Stake as Revenue Hits Record High

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ: INSM) revealed 29 unusual trades.